Krystal Biotech, Inc. (KRYS) - Stock Analysis
Last updated: Jan 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Selected as a speculative near-term buy ahead of Nov 3 earnings supported by FDA label expansion, upcoming European/Japanese launches, strong margins, and positive biotech sector trends, with cautious risk management due to seasonal sales softness and inventory build.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Cash surplus ⢠High margins ⢠Elevated valuation KRYS is extremely cashârich and lowâlevered with very strong recent margins and solid FCF, but elevated market multiples and a oneâtime Q3 tax item suggest caution on sustainability and valuation.
Price Behavior
Key Price Behavior Insights: ⢠Steady climb ⢠Support holding ⢠Short-term overbought Support Level: $240â$245 Resistance Level: $272 KRYS has shown a bullish run over the last month, rising from ~ $240 to $270+ with support holding near $240â$245 but short-term overbought risk after a sharp advance that could prompt pullback before any breakout above $272.
Sentiment & News
Key News Insights: ⢠Vyjuvek traction ⢠Strong 2025 guidance ⢠Advancing pipeline Krystal Biotech is gaining momentum as strong Vyjuvek sales, $388â$389M 2025 revenue guidance, a $955M cash runway, positive analyst ratings, and encouraging KB407 pipeline data drive upside.
AI Summary
Krystal has transitioned into a cashârich, early commercial growth company where VYJUVEK adoption (and nearâterm revenue execution) plus a few binary pipeline readouts now drive valuationâcash reduces financing risk but elevated multiples leave shares highly vulnerable to execution or clinical disappointments.
Description
Krystal Biotech is a clinical-stage biotechnology company developing redosable gene therapies for serious, primarily rare, dermatologic and genetic conditions. Its lead candidate, beremagene geperpavec (B-VEC), is in Phase III for dystrophic epidermolysis bullosa, while a portfolio of other programs spans early- and preclinical development for congenital ichthyosis, netherton syndrome, cystic fibrosis and multiple dermatology indications including aesthetic applications. The company was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | KRYS | Krystal Biotech, Inc. | Selected as a speculative near-term buy ahead of Nov 3 earnings supported by FDA label expansion, upcoming European/Japanese launches, strong margins, and positive biotech sector trends, with cautious risk management due to seasonal sales softness and inventory build. | Closed | +0.9% |